US$ 21.96
negative effects of glp 1 agonists Adverse GLP-1 class drugs. Gastrointestinal issues are GLP-1 receptor agonists are increasingly
Description
10.1111/obr.12465

5 Discussion SID is a frequent complication of GCs therapy, with limited guidance regarding optimal management strategies

In this study, researchers analyzed data from more than 450,000 adults with type 2 diabetes who started either a GLP-1 drug or a dipeptidyl peptidase-4 inhibitor (known as DPP-4 inhibitor)
The increasing prevalence of such disorders necessitates government organizations to launch initiatives to reduce disease prevalence
Adverse drug reactions of GLP-1 agonists: A systematic review of case reports
